Restenosis Therapeutic Pipeline and Development Review H1 2015 Market Research Report

DALLAS, April 1, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Restenosis - Pipeline Review, H1 2015" therapeutic market research report of 56 pages with latest updates, data and information to its online business intelligence library.

The report "Restenosis - Pipeline Review, H1 2015" report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Restenosis is a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.

It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects. Companies discussed in this report include advanceCor GmbH, CSPC Pharmaceutical Group Limited, CytoTools AG, Resverlogix Corp., Shire Plc, Viron Therapeutics, Inc., XBiotech USA, Inc.

Drug Profiles discussed in this report include Annexin A-5, Antibody Conjugate for Restenosis, butylphthalide, COR-3, CV-18C3, HMW-02Ak, HMW-02Ap, HO-3867, LDH-DDART, PVS-10200, Small Molecules for Cardiovascular Diseases, Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury, VAN 10-4, VT-214. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=314346 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease; Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites; Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease.

Scope 

• The report provides a snapshot of the global therapeutic landscape of Restenosis
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Restenosis and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Restenosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Restenosis pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Restenosis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

More reports on Therapeutics Market:

Cat Allergy - Pipeline Review, H2 2014 

This report provides comprehensive information on the therapeutic development for Cat Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include ALK-Abello A/S, Amgen Inc., Biomay AG, Circassia Pharmaceuticals plc, Laboratorios LETI S.L. Complete report available at http://www.rnrmarketresearch.com/cat-allergy-pipeline-review-h2-2014-market-report.html .

Urinary Incontinence - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Urinary Incontinence. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities Companies discussed in this report include Allergan, Inc., Astellas Pharma Inc., Beech Tree Labs, Inc., Cook MyoSite Incorporated, Evotec AG, FemmePharma Global Healthcare, Inc., Innovacell Biotechnologie AG, Recordati S.p.A., TheraVida, Inc. Complete report available at http://www.rnrmarketresearch.com/urinary-incontinence-pipeline-review-h1-2015-market-report.html .

Charcot-Marie-Tooth Disease - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Charcot-Marie-Tooth Disease. The report reviews key players involved in the therapeutics development for Charcot-Marie-Tooth Disease and enlists all their major and minor projects. Companies discussed in this report include Addex Therapeutics Ltd, Genzyme Corporation, PharmatrophiX, Inc., Pharnext SAS. Complete report available at http://www.rnrmarketresearch.com/charcot-marie-tooth-disease-pipeline-review-h1-2015-market-report.html .

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection. The report reviews key pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Companies discussed in this report include AlphaVax, Inc., CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Kineta, Inc., Myelo Therapeutics GmbH, Novavax, Inc., Planet Biotechnology Inc., Protein Sciences Corporation. Complete report available at http://www.rnrmarketresearch.com/severe-acute-respiratory-syndrome-sars-coronavirus-infection-pipeline-review-h1-2015-market-report.html .

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com